文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

RNA中的甲基腺苷修饰：从调控作用到在癌症中的治疗意义

Methyladenosine Modification in RNAs: From Regulatory Roles to Therapeutic Implications in Cancer.

作者信息

Qu Xiaolin, Zhang Yongqiu, Sang Xianzheng, Ren Ding, Zhao Hong, Wong Stephen T C

机构信息

Department of Neurosurgery, Changzheng Hospital, Naval Medical University, Shanghai 200003, China.

Department of Radiology, PLA No. 905 Hospital, Naval Medical University, Shanghai 200050, China.

出版信息

Cancers (Basel). 2022 Jun 29;14(13):3195. doi: 10.3390/cancers14133195.

DOI:10.3390/cancers14133195
PMID:35804965
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9264946/
Abstract

Methyladenosine modifications are the most abundant RNA modifications, including N6-methyladenosine (mA), N1-methyladenosine (mA), and 2'-O-methyladenosine (mA). As reversible epigenetic modifications, methyladenosine modifications in eukaryotic RNAs are not invariable. Drastic alterations of mA are found in a variety of diseases, including cancers. Dynamic changes of mA modification induced by abnormal methyltransferase, demethylases, and readers can regulate cancer progression via interfering with the splicing, localization, translation, and stability of mRNAs. Meanwhile, mA, mA, and mA modifications also exert regulatory effects on noncoding RNAs in cancer progression. In this paper, we reviewed recent findings concerning the underlying biomechanism of methyladenosine modifications in oncogenesis and metastasis and discussed the therapeutic potential of methyladenosine modifications in cancer treatments.

摘要

甲基腺苷修饰是最为丰富的RNA修饰类型，包括N6-甲基腺苷（m6A）、N1-甲基腺苷（m1A）和2'-O-甲基腺苷（mAm）。作为可逆的表观遗传修饰，真核生物RNA中的甲基腺苷修饰并非一成不变。在包括癌症在内的多种疾病中都发现了m6A的显著改变。由异常的甲基转移酶、去甲基酶和阅读蛋白诱导的m6A修饰动态变化，可通过干扰mRNA的剪接、定位、翻译和稳定性来调节癌症进展。同时，m6A、m1A和mAm修饰在癌症进展过程中对非编码RNA也发挥着调控作用。在本文中，我们综述了有关甲基腺苷修饰在肿瘤发生和转移中的潜在生物机制的最新研究结果，并讨论了甲基腺苷修饰在癌症治疗中的治疗潜力。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7fe6/9264946/ed76c612648a/cancers-14-03195-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7fe6/9264946/2bed55620c1d/cancers-14-03195-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7fe6/9264946/3d017afcc108/cancers-14-03195-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7fe6/9264946/fe8da2ee852d/cancers-14-03195-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7fe6/9264946/5215c21ad9a9/cancers-14-03195-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7fe6/9264946/ed76c612648a/cancers-14-03195-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7fe6/9264946/2bed55620c1d/cancers-14-03195-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7fe6/9264946/3d017afcc108/cancers-14-03195-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7fe6/9264946/fe8da2ee852d/cancers-14-03195-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7fe6/9264946/5215c21ad9a9/cancers-14-03195-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7fe6/9264946/ed76c612648a/cancers-14-03195-g005.jpg

相似文献

[1]
Methyladenosine Modification in RNAs: From Regulatory Roles to Therapeutic Implications in Cancer.

Cancers (Basel). 2022-6-29

[2]
N6-Methyladenosine-Sculpted Regulatory Landscape of Noncoding RNA.

Front Oncol. 2021-10-15

[3]
Epigenetic Regulation of mA Modifications in Human Cancer.

Mol Ther Nucleic Acids. 2020-3-6

[4]
Main N6-Methyladenosine Readers: YTH Family Proteins in Cancers.

Front Oncol. 2021-4-13

[5]
Effects of N-Methyladenosine Modification on Cancer Progression: Molecular Mechanisms and Cancer Therapy.

Front Oncol. 2022-5-30

[6]
The roles of N6-methyladenosine and its target regulatory noncoding RNAs in tumors: classification, mechanisms, and potential therapeutic implications.

Exp Mol Med. 2023-3

[7]
The functions of N6-methyladenosine modification in lncRNAs.

Genes Dis. 2020-3-19

[8]
N6-methyladenine RNA modification and cancer.

Oncol Lett. 2020-8

[9]
RNA N6-Methyladenosine Modifications and Its Roles in Alzheimer's Disease.

Front Cell Neurosci. 2022-3-24

[10]
The role of N6-methyladenosine (mA) in kidney diseases.

Front Med (Lausanne). 2023-9-28

引用本文的文献

[1]
A comprehensive prognostic and immune analysis of in pan-cancer and Philadelphia chromosome-positive acute lymphoblastic leukemia.

Front Immunol. 2025-2-28

[2]
A comprehensive and systematic analysis of Dihydrolipoamide S-acetyltransferase as a novel prognostic biomarker in pan-cancer and glioma.

Oncol Res. 2024

[3]
Transcriptome-wide 1-methyladenosine functional profiling of messenger RNA and long non-coding RNA in bladder cancer.

Front Genet. 2024-2-28

[4]
The Crucial Findings Derived from the Special Issue "Inside Cancer Genomics: From Structure to Therapy".

Cancers (Basel). 2023-7-4

[5]
METTL3-mediated m6A modification of LINC00839 maintains glioma stem cells and radiation resistance by activating Wnt/β-catenin signaling.

Cell Death Dis. 2023-7-12

[6]
METTL3/YTHDF2 m6A axis promotes the malignant progression of bladder cancer by epigenetically suppressing RRAS.

Oncol Rep. 2023-5

[7]
An overview of the effects and mechanisms of m6 A methylation on innate immune cells in sepsis.

Front Immunol. 2022

[8]
RNA Modifications Meet Tumors.

Cancer Manag Res. 2022-11-22

[9]
M6AREG: m6A-centered regulation of disease development and drug response.

Nucleic Acids Res. 2023-1-6

本文引用的文献

[1]
Eltrombopag as an Allosteric Inhibitor of the METTL3-14 Complex Affecting the mA Methylation of RNA in Acute Myeloid Leukemia Cells.

Pharmaceuticals (Basel). 2022-4-1

[2]
TRMT6/61A-dependent base methylation of tRNA-derived fragments regulates gene-silencing activity and the unfolded protein response in bladder cancer.

Nat Commun. 2022-4-20

[3]
A Novel m1A-Score Model Correlated With the Immune Microenvironment Predicts Prognosis in Hepatocellular Carcinoma.

Front Immunol. 2022

[4]
FTO in cancer: functions, molecular mechanisms, and therapeutic implications.

Trends Cancer. 2022-7

[5]
Lactylation-driven METTL3-mediated RNA mA modification promotes immunosuppression of tumor-infiltrating myeloid cells.

Mol Cell. 2022-5-5

[6]
Oncogenic and Tumor-Suppressive Functions of the RNA Demethylase FTO.

Cancer Res. 2022-6-15

[7]
mA RNA modifications are measured at single-base resolution across the mammalian transcriptome.

Nat Biotechnol. 2022-8

[8]
METTL3/IGF2BP3 axis inhibits tumor immune surveillance by upregulating N-methyladenosine modification of PD-L1 mRNA in breast cancer.

Mol Cancer. 2022-2-23

[9]
YTHDF2 Inhibits the Migration and Invasion of Lung Adenocarcinoma by Negatively Regulating the FAM83D-TGFβ1-SMAD2/3 Pathway.

Front Oncol. 2022-2-2

[10]
METTL14-mediated mA modification of circORC5 suppresses gastric cancer progression by regulating miR-30c-2-3p/AKT1S1 axis.

Mol Cancer. 2022-2-14

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索